Neumora Therapeutics (NMRA) Depreciation & Amortization (CF) (2022 - 2026)

Neumora Therapeutics' Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $8000.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 94.9% year-over-year to $8000.0; the TTM figure through Mar 2026 stood at $59000.0 (down 90.63% YoY), while the FY2025 annual figure was $208000.0, down 67.04% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $8000.0, down from $9000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $198000.0 in Q4 2023, with the low at $8000.0 in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $157000.0 (2024), against an average of $121428.6.
• The sharpest annual moves came in 2023 and 2026: Depreciation & Amortization (CF) increased 29.41% in 2023, then tumbled 94.9% in 2026.
• Neumora Therapeutics' Depreciation & Amortization (CF) stood at $153000.0 in 2022, then grew by 29.41% to $198000.0 in 2023, then retreated by 20.71% to $157000.0 in 2024, then slumped by 94.27% to $9000.0 in 2025, then retreated by 11.11% to $8000.0 in 2026.
• Business Quant data shows NMRA's Depreciation & Amortization (CF) at $8000.0 in Q1 2026, $9000.0 in Q4 2025, and $23000.0 in Q3 2025.